Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrystal Amber Regulatory News (CRS)

Share Price Information for Crystal Amber (CRS)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.00 (0.00%)
Bid:
102.00
Ask:
106.00
Spread: 4.00 (3.922%)
Market Cap: £61.92m
CRS Live PriceLast checked at - London Stock Exchange

Intraday Crystal Amber Share Chart

Share Buyback Programme

20 Nov 2025 07:00

RNS Number : 2757I
Crystal Amber Fund Limited
20 November 2025
Β 

20 November 2025

Β 

Crystal Amber Fund Limited

("Crystal Amber Fund", the "Company" or the "Fund")

Β 

Share Buyback Programme

Β 

Crystal Amber Fund announces that it intends to continue to conduct on-market purchasesΒ to buyback the Company's shares under a share buyback programme. Since 15 December 2023, approximately Β£23.3 million has been returned to shareholders in share buybacks and in order to continue this and reduce the Company's share capital, from now until 2 December 2025 the Company intends to repurchase ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") up to an aggregate amount of Β£400,000 or 300,000 Ordinary Shares, pursuant to the authority obtained at the Company's annual general meeting on 13 December 2024 (the "Buyback").

Β 

The Company has appointed Winterflood Securities Limited ("Winterflood") to execute and manage the Buyback and has given an irrevocable instruction to Winterflood to make market purchases of Ordinary Shares on its behalf, independently of the Company. Winterflood will make its trading decisions in relation to the Ordinary Shares independently of and uninfluenced by the Company with such trading decisions being in line with the terms of the Buyback.

Β 

The maximumΒ price which may be paid by the Company per Ordinary Share shall not be more than the higher of:

a. Β 105 per cent of the average of the middle market quotations for an Ordinary Share as derived from the AIM market of the London Stock Exchange plc for the five business days immediately preceding the day on which the purchase is made; and

b. the value of an Ordinary Share calculated on the basis of the higher of the price quoted for (i) the last independent trade of and (ii) the highest current independent bid for the Ordinary Shares.

Β 

Due to the relatively low liquidity in the Ordinary Shares, the Company may purchase Ordinary Shares pursuant to the Buyback on any trading day materially in excess of 25 per cent of the average daily volume, being the limit prescribed pursuant to Article 5(1) of the EU Market Abuse Regulation (2014/596/EU) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) ("UK MAR") and accordingly, the Company may not benefit from that exemption.

Β 

There is no guarantee that the Buyback programme will be implemented in full or that any purchases will be made.Β The Company reserves the right to bring a halt to the Buyback under circumstances that it deems to be appropriate and in accordance with relevant law and regulation.

Β 

The Company will make further announcements in due course following any share purchases conducted through the Buyback. Ordinary Shares purchased in the Buyback will be cancelled in due course.

Β 

Β 

For further enquiries please contact:

Β 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com

Β 

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Ashur Joseph

Tel: 020 3328 5656

Β 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

Β 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCUKVORVNUAAUA
Date   Source Headline
16th Aug 20249:45 amRNSDirector/PDMR Shareholding
16th Aug 20249:43 amRNSTransaction in Own Shares and Total Voting Rights
15th Aug 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Aug 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
12th Aug 20247:00 amRNSExtension to Share Buyback Programme
31st Jul 20245:00 pmRNSTotal Voting Rights
31st Jul 202411:50 amRNSInvestee company update: Morphic Medical Inc.
31st Jul 202411:07 amRNSMonthly Net Asset Value
26th Jul 20244:06 pmRNSTransaction in Own Shares and Total Voting Rights
23rd Jul 20246:04 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Jul 20245:42 pmRNSTransaction in Own Shares and Total Voting Rights
28th Jun 20245:15 pmRNSTotal Voting Rights
21st Jun 20245:00 pmRNSTransaction in Own Shares and Total Voting Rights
19th Jun 202410:07 amRNSMonthly Net Asset Value
18th Jun 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
7th Jun 20244:49 pmRNSTransaction in Own Shares and Total Voting Rights
6th Jun 20245:15 pmRNSTransaction in Own Shares and Total Voting Rights
5th Jun 20245:43 pmRNSTransaction in Own Shares and Total Voting Rights
4th Jun 202412:11 pmRNSHolding(s) in Company
4th Jun 202412:11 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNSMorphic Medical – FDA approval of study amendments
3rd Jun 20245:33 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20247:00 amRNSTotal Voting Rights
31st May 20245:39 pmRNSTransaction in Own Shares
31st May 20247:00 amRNSTransaction in Own Shares
23rd May 20241:21 pmRNSMonthly Net Asset Value
23rd May 20247:00 amRNSExtension to Share Buyback Programme
22nd May 20247:00 amRNSTransaction in Own Shares
17th May 20245:49 pmRNSTransaction in Own Shares
3rd May 20246:22 pmRNSHolding(s) in Company
2nd May 202412:37 pmRNSHolding(s) in Company
1st May 20245:22 pmRNSTransaction in Own Shares
30th Apr 20245:37 pmRNSTotal Voting Rights
29th Apr 20243:26 pmRNSHolding(s) in Company
26th Apr 20245:27 pmRNSTransaction in Own Shares
25th Apr 20247:00 amRNSHolding(s) in Company
24th Apr 20244:00 pmRNSMonthly Net Asset Value
24th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20246:22 pmRNSTransaction in Own Shares
10th Apr 20249:34 amRNSTransaction in Own Shares
3rd Apr 20244:44 pmRNSMonthly Net Asset Value
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:30 pmRNSExtension to Share Buyback Programme
28th Mar 20246:01 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSHalf-year Report
27th Mar 20246:27 pmRNSTransaction in Own Shares
22nd Mar 20245:09 pmRNSTransaction in Own Shares
18th Mar 20245:29 pmRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20245:30 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.